However, it was reported that inflammatory cytokines which can alter levels of CYP expression (e.g., IL-6 reduction of CYP3A levels), resulted in a 28% decrease in midazolam metabolic intrinsic clearance in cancer patients following an oral dose [24]. This evidence concerns the gene IL6 and cancer.